L. Vassilev

发表

Oncolytic adenovirus and doxorubicin‐based chemotherapy results in synergistic antitumor activity against soft‐tissue sarcoma

A. Hemminki, M. Siurala, Simona Bramante, 2015, International journal of cancer.

Serotype chimeric oncolytic adenovirus coding for GM‐CSF for treatment of sarcoma in rodents and humans

A. Hemminki, Simona Bramante, L. Vassilev, 2014, International journal of cancer.

Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy

T. D. de Gruijl, Hongjie Wang, A. Hemminki, 2017, Oncoimmunology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Synergistic anti‐tumor efficacy of immunogenic adenovirus ONCOS‐102 (Ad5/3‐D24‐GM‐CSF) and standard of care chemotherapy in preclinical mesothelioma model

L. Vassilev, M. Hirvinen, V. Cerullo, 2016, International journal of cancer.

Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+ T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer

J. Karbach, K. Partanen, N. Linder, 2015, Oncoimmunology.

Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues.

A. Hemminki, Simona Bramante, L. Vassilev, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization

J. Karbach, K. Partanen, N. Linder, 2014, Oncoimmunology.

Retrospective, Registry-based, Cohort Investigation of Clinical Outcomes in Patients with Cutaneous Squamous Cell Carcinoma and Basal Cell Carcinoma in Finland

L. Ukkola-Vuoti, V. Kähäri, L. Vassilev, 2022, Acta dermato-venereologica.

Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus.

N. Linder, Riku Turkki, J. Lundin, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 – Support for clinical studies on advanced cancer treatment

A. Hemminki, L. Vassilev, V. Cerullo, 2017, PloS one.

Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers

J. Karbach, K. Partanen, N. Linder, 2016, Journal of Immunotherapy for Cancer.

Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM‐CSF: Results in vitro, in rodents and in humans

D. Nettelbeck, A. Hemminki, Simona Bramante, 2015, International journal of cancer.

Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer

A. Hemminki, M. Siurala, Simona Bramante, 2016, Oncoimmunology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus.

N. Linder, Riku Turkki, J. Lundin, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

Real-world evidence of multiple myeloma treated from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, Finland.

K. Porkka, L. Vassilev, T. Ranki, 2023, Future oncology.